Promising combo for brain metastases falls short in early trial
NCT ID NCT07166367
First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 41 times
Summary
This study tested a combination of two drugs (ASLAN001 and capecitabine) in people with HER2-positive breast cancer that had spread to the brain and was growing despite prior radiation. Only 3 participants were enrolled before the study was stopped early. The goal was to see if the treatment could shrink brain tumors, but the small size limits what we can learn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Centre Singapore
Singapore, 169610, Singapore
Conditions
Explore the condition pages connected to this study.